ADRX 0405
Alternative Names: ADRX-0405Latest Information Update: 17 Jun 2025
At a glance
- Originator Adcentrx Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 29 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Hormone refratory) in USA (unspecified route) (NCT06710379)
- 04 Apr 2024 Preclinical trials in Cancer in USA (unspecified route), prior to April 2024 (Adcentrx Therapeutics pipeline, April 2024)